Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
While we chose to divide our etiologies into three categorie
2024-11-11

While we chose to divide our etiologies into three categories, it should be noted that such division has certain limitations. Even though URIs and the common cold are considered mainly viral in origin and rhinosinusitis mainly bacterial in origin,26, 27 there is considerable overlap between these co
-
No starting dose adjustment is needed for
2024-11-11

No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad
-
In the present study a
2024-11-11

In the present study, a splice acceptor site mutation (c.1769-1G > C) was identified in AR gene from patients with CAIS. The c.1769-1G > C mutation results in replacement of the normal sequence (CAG/G) with a new sequence (CAC/G) at the splice acceptor site of intron 2. In the splice acceptor site r
-
SKF 81297 hydrobromide synthesis br Results and discussion I
2024-11-11

Results and discussion In order to investigate the assembly dynamics and aggregate structures of Aβ16-22, twelve molecular systems with the number of peptides varying from 1 to 12 were studied. In all simulations, the same peptide concentration (~15 mM) was maintained by adjusting the dimensions
-
An unbiased evaluation of hepatic mRNA was performed
2024-11-11

An unbiased evaluation of hepatic mRNA was performed to assess the impact of hepatocyte AMPK activation on the transcriptome. The expression of 913 genes were altered in control mice after chronic PF-06409577 treatment, 188 genes were affected by knocking out AMPK in hepatocytes, and expression of 2
-
br Acknowledgements This work was supported by
2024-11-11

Acknowledgements This work was supported by Programme Grants from the MRC and the Wellcome Trust (SGC-C and MF). CB was in receipt of a Marie Curie Intra-European Fellowship during part of this work. We thank past and present members of our group for numerous valuable discussions throughout these
-
Through systematic deletion of AhR in specific cell types Di
2024-11-11

Through systematic d-amphetamine of AhR in specific cell types, Di Meglio et al. (2014) revealed that AhR in keratinocytes and fibroblasts are key to the exacerbated psoriatic phenotype induced by IMQ in AhR-deficient mice. This emphasizes the crosstalk between keratinocytes and the immune system t
-
br Material and methods br Results
2024-11-09

Material and methods Results Discussion To develop a novel regenerative and/or neuroprotective therapy for optic neuropathy, including glaucoma, numerous studies have tested new candidates favorable to RGC survival and axon regeneration. Among the many candidate drugs, AdoR modulators are
-
rt-pcr Many metalloenzyme inhibitors consist of
2024-11-09

Many metalloenzyme inhibitors consist of two chemical components: the MBG, the portion of the inhibitor designed to bind to the metal, and the scaffold, the portion of the inhibitor recognized by the amino rt-pcr residues that form the substrate-binding site of the metalloenzyme. The MGB is often a
-
A rational approach for the design of new
2024-11-09

A rational approach for the design of new steroid compounds as possible competitive inhibitors of CYP17 include chemical modification at C17 of the enzyme's natural substrates, pregnenolone (1) and progesterone (2), introducing groups with moderate to strong dipole properties at C20, such as oxime a
-
Autophagy is a highly conservative intracellular bulk
2024-11-09

Autophagy is a highly conservative intracellular bulk degradation process including three major forms namely microautophagy, chaperone-mediated autophagy and macroautophagy. A large number of evidence has depicted a pivotal role for autophagy in the maintenance of cardiac geometry and contractile fu
-
Pompe disease is accompanied by the deficiency of the
2024-11-09

Pompe disease is accompanied by the deficiency of the lysosomal α-1,4-glucosidase that makes the isoprenaline unable to hydrolyze glycogen to glucose, thereby resulting in the accumulation of glycogen in lysosomes, especially in skeletal muscles and cardiac tissues. This accumulation results in the
-
The skin permeability barrier is important for the
2024-11-09

The skin permeability barrier is important for the prevention of loss of water and electrolytes from inside the body and for protection against the invasion of external pathogens, allergens, and harmful compounds. Multi-layered lipids, called lipid lamellae, are present in the outermost cell layer o
-
SC-514 receptor Finally the comparison between data obtained
2024-11-09

Finally, the comparison between data obtained by antioxidant assays in in vitro cultured cells [11], [12] and in liposomes has disclosed the possibility to choose more confidently “the better phenolipid” of a series of fatty acids esters antioxidant derivatives. Looking at the physical parameters th
-
The most common grade AEs associated
2024-11-08

The most common grade 3/4 AEs associated with the soluble fusion protein ziv-aflibercept are neutropenia, hypertension, and diarrhea [63]. In general, medical oncologists associate ziv-aflibercept with worse toxicity than BV, and meta-analyses of clinical trial data with ziv-aflibercept or BV suppor
15728 records 54/1049 page Previous Next First page 上5页 5152535455 下5页 Last page